Opioid Use Disorder (OUD) Market to Surpass USD 11.8 Billion by 2035, Driven by Rising Treatment Adoption

According to the MarketGenics report, the opioid use disorder (OUD) market is anticipated to grow from USD 4.2 Billion in 2025 to USD 11.8 Billion in 2035 at a CAGR of 10.9% during the forecast. The opioid use disorder (OUD) market is growing rapidly due to increased incidences of opioid addiction worldwide and increasing funding for integrated care models. Innovations are happening in telemedicine and remote monitoring in North America and Europe due to work being done by private companies and technology vendors. There are also VR-based clinician training programs made available to improve workforce capacities and increase treatment delivery.

Additionally, AI-powered platforms are being utilized for treatment plans, operationalized as scalable care solutions that offer personalized treatment options as the demand grows in developed and emerging markets. Trend transitions to Client-based care, called in-home care management, is also a catalyst for the growth of this market, as well as with the COVID-19 pandemic and recent changes in healthcare policies for remote care. There is significant investment in cybersecurity for connected treatment devices to keep data secure for sensitive patient information.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Opioid Use Disorder (OUD) Market Research Report: https://marketgenics.co/press-releases/opioid-use-disorder-oud-market-58181

Key Driver, Restraint, and Growth Opportunity Defining the Global Opioid Use Disorder (OUD) Market

The global market for opioid use disorder (OUD) is on the rise due to the increasing rates of opioid addiction and demand for more accessible and patient-centered treatment options. Advances in telemedicine, digital health platforms, and AI-enabled digital monitoring are increasing the personalization of care and the possibility of continuous care and monitoring from the comfort of the patient's home, which will also continue to encourage growth in the market. Increased awareness campaigns and government-level initiatives are also leading to increasing diagnosis of opioid use disorder and uptake of OUD treatment globally.

In spite of this growth trajectory, challenges still remain such as poor insurance reimbursement, shortages in the addiction treatment workforce, regulatory issues, limitations with safety-monitoring and care coordination, stigma, and fragmented health care systems meaning patients cannot access high-quality care.

Nevertheless, opportunities also exist at the intersection of developing digital health innovations and the demand for patient-centered therapies for use in or around their homes. Investment in infrastructure around health care services, technology-based care models, and more collaborative care across sectors will help to sustain growth and create new opportunities in the OUD market.

To know more about the Opioid Use Disorder (OUD) Market - Download our Sample Report: https://marketgenics.co/download-report-sample/opioid-use-disorder-oud-market-58181

Impact of Global Tariff Policies on the Global Opioid Use Disorder (OUD) Market Growth and Strategy

International tariffs create a negative impact on the OUD market by increasing the price of critical medication, digital health devices, and treatment technology used in OUD. Tariffs on pharmaceuticals, or remote monitoring equipment, coming from places like China or Mexico will increase the price of medications and supplies, and may limit patients' access to necessary treatments for their OUD.

Owing to which the supply chain issues, manufacturers are increasing the diversification of their sourcing of supplies as a way to reduce dependence on a foreign supplier, and they are investing in U.S. production capabilities. Manufacturers are also adopting more innovative technologies and utilizing more efficient processes to continue controlling costs. Policymakers will need to consider the implications of tariff policy on affordability and accessibility of OUD treatments to provide equitable care for patients.

Buy Now: https://marketgenics.co/buy/opioid-use-disorder-oud-market-58181

Recent Development and Strategic Overview:

In February 2025, Braeburn Pharmaceuticals announced that since launching in the U.S. in 2023, BRIXADI had been administered in over 75,000 patients for OUD treatment. Since, patient demand for real-time treatment management grew, Braeburn also implemented predictive analytics tools into their patient support program to help healthcare providers identify early signs of non-adherence, engage patients, and reduce treatment dropout rates.

In May 2025, Alkermes PLC reported that more than 60,000 patients were treated over the previous year with VIVITROL, the company's extended-release injectable naltrexone. To improve clinical outcomes, Alkermes created a cloud-based platform to provide risk assessment and personalized treatment planning using AI to providers. Early results from this platform indicated a 22% improvement of treatment continuity, especially in correctional and community health settings.

Get a preview of our Opioid Use Disorder (OUD) Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/opioid-use-disorder-oud-market-58181

Key Trend: Integration of Digital Health and AI for Personalized OUD Management

The market of opioids use disorder (OUD) is strongly moving toward new integration of digital health tools including mobile apps, artificial-intelligence enabled adherence monitoring and virtual counseling to personalize treatment and improve patient outcomes. These technologies will help capture real-time data regarding patient behavior, which will assist with early intervention before a patient relapse.

In March 2025, for example, the biotech company introduced an artificial intelligence-enabled platform that integrates digital biomarkers and medication-assisted treatment (MAT) to personalize patient management and provide real-time support to patients to increase engagement and retention.
The adoption of technology-enabled care approaches not only promote increased treatment efficacy but they also ameliorate challenges associated with complexity of long-term management and scalability - which, once again, leads to increased adoption by touched system of healthcare providers, and payers.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.